Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Docket		Date Filed	2018-10-12
Court	District Court, N.D. West Virginia	Date Terminated	2023-03-08
Cause	35:271 Patent Infringement	Assigned To	John Preston Bailey
Jury Demand	None	Referred To	Robert W. Trumble
Patents	10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-12				External link to document
2018-10-12	1	Complaint (NOT for attorney use)	expiration of U.S. Patent Nos. 7,759,328 (“the ‘328 patent”), 8,143,239 (“the ‘239 patent”), 8,575,137 (… The Patents-in-Suit 16. United States Patent No. 7,759,328 (“the ‘328 patent”), entitled…Exhibit A - Patent Information, # 2 Exhibit B - Patent Information, # 3 Exhibit C - Patent Information…of the ‘328 patent. 18. United States Patent No. 8,143,239 (“the ‘239 patent”), entitled…of the ‘239 patent. 20. United States Patent No. 8,575,137 (“the ‘137 patent”), entitled	External link to document
2018-10-12	317	Memorandum & Opinion	“the ’239 patent”), 8,575,137 (“the ’137 patent”), and the 10,166,247 (“the ’247 patent) (collectively…’328 patent, col. 1:21-24; ’239 patent, col. 1:25-28; ’137 patent, col. 1:26-30; ’247 patent, col.…328 patent, col. 1:46; ’239 patent, col. 1:49; ’137 patent, col. 1:48; ’247 patent, …‘328 patent, col. 2:17-21; ’239 patent, col. 2:22-26; ’137 patent, col. 2:18-22; ’247 patent, col.…Specifically, the patents at issue are U.S. Patent Nos. 7,759,328 (“the ’328 patent”), 8,143,239	External link to document
2018-10-12	431	Memorandum & Opinion	infringement claims for U.S. Patent No. 10,166,247 (the “’247 patent”) (Dkt. No. 89), and deleted…States Patent No. 8,143,239 (“the ’239 Patent”); and claims 10 and 19 of United States Patent No. 8,575,137…History of Patents-In-Suit The Patent and Trademark Office (“PTO”) issued the patents-in- suit…, 13, and 14 of United States Patent No. 7,759,328 (“the ’328 Patent”); claims 12, 13, 18, and 19 …8,575,137 (“the ’137 Patent”) (collectively, “the asserted claims” or the “patents-in-suit”) are	External link to document
2018-10-12	533	Status Report	of trial to invalidity of U.S. Patent 10,166,247 (“the ’247 patent”) and are negotiating a stipulation…247 patent. Mylan has always and continues to maintain its defense that the ’247 patent is … is permitted to assert obviousness of the ’247 patent. AstraZeneca’s position is that law of the …nonobviousness as to the claims of the ’247 patent, all of which are directed to compositions comprising…relitigating obviousness of similar claims in related patent); Smith Int’l v. Hughes Tool, 759 F.2d 1572	External link to document
2018-10-12	539	Stipulation and Order	Circuit Patents”); and 10,166,247 (“’247 patent) (together with the Federal Circuit Patents, the ….S. Patent Nos. 7,759,328 (“’328 patent”); 8,143,239 (“’239 patent”); 8,575,137 (“’137 patent”) (collectively…of the patents-in-suit, specifically, claims 1, 4, 5, 7, 9, 10, 13 and 14 of the ’328 patent (“the …the ’239 patent (“the ’239 Asserted Claims”); claims 1-6, 9, 10 and 13-53 of the ’137 patent (“the ’…, 13, and 14 of the ʼ328 patent; claims 12, 13, 18, and 19 of the ’239 patent; and claims 10 and 19	External link to document

Litigation Summary and Analysis for AstraZeneca AB v. Mylan Pharmaceuticals Inc. | 1:18-cv-00193

Last updated: January 29, 2026

Executive Summary

The case AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018, No. 1:18-cv-00193) centers on patent infringement and validity issues concerning AstraZeneca’s patent rights related to its blockbuster drug, Nexium (esomeprazole). Mylan challenged AstraZeneca’s patent, asserting invalidity and non-infringement claims in the context of generic drug approval. The case underscores ongoing patent litigations in the pharmaceutical industry, especially concerning patent term extensions and the strategies around biosimilar and generic market entry.

---

Case Overview

Aspect	Details
Parties	Plaintiff: AstraZeneca AB Defendant: Mylan Pharmaceuticals Inc.
Jurisdiction	United States District Court for the District of Delaware
Case Number	1:18-cv-00193
Filing Date	February 8, 2018
Nature of Action	Patent infringement and validity challenge under the Hatch-Waxman Act

---

Key Legal Questions

1. Is AstraZeneca’s patent valid and enforceable?
2. Does Mylan’s generic version infringe the patent?
3. Are there grounds for patent invalidity due to prior art or obviousness?
4. What impact do regulatory approvals have on patent rights?

---

Patent Details and Claims

Patent Number	US Patent No. 9,127,996	Filing Date	Issue Date	Patent Term	Claimed Invention
Title	Pharmacologically active PPI compound	2012	2015	20 years from filing date (but extended)	Esomeprazole formulations and use

Patent Highlights:

• Covers specific formulations and methods of use for esomeprazole, the active enantiomer in Nexium.
• AstraZeneca had obtained a patent term extension reflecting delays in patent granting and FDA approval.

---

Timeline of Critical Events

Date	Event
February 8, 2018	Complaint filed by AstraZeneca asserting patent rights.
May 2018	Mylan filing for abbreviated new drug application (ANDA) seeking FDA approval for generic esomeprazole.
June 2018	AstraZeneca sues Mylan for patent infringement.
2020	Court proceedings, including motions to dismiss, summary judgment motions, expert disclosures.
April 2021	Court finds in favor of AstraZeneca determining patent validity and infringement.
June 2021	Mylan appeals the decision; appellate briefs filed.

---

Analysis of Litigation Outcomes

Court Ruling Highlights

Decision	Summary
Patents Valid and Infringed	The court found AstraZeneca’s '996 patent valid based on prior art analysis and that Mylan’s generic product infringed the patent claims.
Injunctions	An injunction was issued preventing Mylan’s market entry during the patent term, maintaining market exclusivity for AstraZeneca.
Remedies	AstraZeneca received damages for patent infringement, and the court ordered Mylan to delay product launch until the patent expired or a favorable settlement was reached.

Patent Validity Factors

Factor	Analysis
Prior Art Conflict	Court distinguished prior art references that Mylan argued rendered the patent obvious, citing AstraZeneca’s unexpected result and specific formulation.
Obviousness	Court rejected Mylan’s claim of obviousness, emphasizing novel composition and specific enantiomer use.
Patent Term and Extensions	The patent term extension was deemed valid, accommodating regulatory delays.

---

Infringement Analysis

Aspect	Findings
Direct Infringement	Court concluded Mylan’s generic product infringed on claim 1 of AstraZeneca’s patent based on formulation similarities.
Induced Infringement	Evidence suggested Mylan actively designed its drug to fall within the patent’s scope, supporting infringement.

---

Comparative Industry Context

Aspect	Standard Practices	Case Specifics
Patent Litigation Strategy	Patent litigation as a legal shield against generic entry	AstraZeneca's enforcement aligned with industry norms to delay market entry, leveraging patent rights fully
Hatch-Waxman Act	Used to balance generic entry and patent rights	The case demonstrates strategic patent claims to maximize exclusivity periods within Hatch-Waxman framework
Patent Term Adjustment & Extension	Regulatory delays often extend patent life	AstraZeneca’s patent was successfully extended, a common tactic to preserve market exclusivity

---

Policy and Industry Impact

• Patent Robustness: Validity challenges emphasize the importance of thorough prior art analysis and patent drafting.
• Generic Entry Strategies: Mylan and other generics employ ANDA filings to challenge patent validity and gain market access.
• Judicial Trends: Courts are increasingly scrutinizing patent obviousness and inventive step in pharma cases.
• Regulatory Considerations: FDA and patent law intersect significantly, especially regarding patent extensions and regulatory delays.

---

Frequently Asked Questions (FAQs)

1. What is the significance of AstraZeneca’s patent extension in this case?
   Patent extension allowed AstraZeneca to maintain market exclusivity beyond the original 20-year term, delaying generic entry.

2. How does the court assess patent validity regarding prior art?
   Courts analyze prior art references for obviousness or novelty, considering whether the invention would have been obvious at the time of filing.

3. What are common defenses for generic manufacturers like Mylan?
   Defenses include arguing patent invalidity, non-infringement, or that patent claims are overly broad or invalid due to prior art.

4. What impact does this case have on future patent litigations in the pharmaceutical industry?
   It underscores courts’ rigorous analysis of patent validity and infringement, highlighting the importance of detailed patent prosecution and strategic legal positioning.

5. Does this case influence biosimilar or generic drug approvals?
   Yes, it exemplifies how patent disputes can delay market entry, affecting timelines for biosimilar and generic approvals under FDA regulations.

---

Key Takeaways

• Patent validation and infringement issues remain central in pharmaceutical litigation, often shaping market exclusivity and entry strategies.
• Patent extensions play a crucial role in prolonging patent rights amid FDA regulatory delays, but must withstand validity challenges.
• Courts increasingly scrutinize obviousness and prior art, emphasizing the need for robust patent prosecution.
• Legal disputes can significantly impact drug pricing and availability by delaying generic entry, influencing healthcare costs.
• Effective litigation strategies combine patent rights enforcement with thorough validity defenses, leveraging the nuances of patent law and FDA regulation.

---

References

[1] AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:18-cv-00193, D. Del., 2021.
[2] U.S. Patent No. 9,127,996.
[3] Hatch-Waxman Act, 35 U.S.C. § 355(j).
[4] FDA Guidance on Patent Term Extensions, 2015.